January 24, 2021

The virtual 38th Annual Miami Breast Cancer Conference®, hosted by Physicians’ Education Resource®, LLC will feature presentations from industry thought leaders on innovations in the arena of breast cancer treatment, including topics about systemic therapy and beyond.

January 24, 2021

This was the fastest vaccine development program in history, and it’s not even close. David Pride, MD, PhD, a microbiologist at the University of California, San Diego, estimates that vaccines typically take 10 to 15 years to develop. Until the COVID-19 pandemic, the fastest development timeline was 4 years, for the mumps vaccine.

January 23, 2021

During a Targeted Oncology Case-Based Peer Perspective Roundtable, Mary Jo J. Fidler, MD, discussed targeting VEGFR and EGFR in patients with non–small cell lung cancer.

January 23, 2021

Andrew Wei, MBBS, PhD, discusses the results from the phase 3 QUAZAR AML-001 Maintenance Trial of CC-486 for patients with acute myeloid leukemia in the first remission after intensive chemotherapy.

January 23, 2021

An exploratory analysis of the phase 3 IMvigor130 trial demonstrated that the benefit of frontline atezolizumab added to gemcitabine and platinum chemotherapy was maintained in patients with urothelial cancer, regardless of the site of the primary tumor.

January 22, 2021

JAK inhibitors designed for the treatment of myelofibrosis address the splenic response and constitutional symptoms associated with the disease, but the agents are inherently myelosuppressive and can exacerbate anemia and thrombocytopenia.

January 22, 2021

In an interview with Targeted Oncology, Senthil Damodaran, MD, PhD, discussed the need for an ESR1-targeted agent for the postmenopausal women with ESR1-positive, locally advanced or metastatic ER-positive/HER2-negative breast cancer.

January 22, 2021

The FDA has granted approval to the combination of nivolumab and cabozantinib as treatment of advanced renal cell carcinoma in the frontline setting.

January 22, 2021

Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma and melanoma received the combination of eganelisib and nivolumab.

January 22, 2021

This week, the FDA granted Priority Review designation to 4 therapies. The designations were across multiple malignancies and cancer-related conditions, including for patients with post-transplant complications, gastric/gastroesophageal junction and esophageal adenocarcinoma, as well as with squamous cell carcinoma of the anal canal.

January 22, 2021

The FDA has accepted a Biologics License Application for retifanlimab, an investigational intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on or who are intolerant of platinum-based chemotherapy and has granted the BLA a Priority Review.

January 22, 2021

Jesus G. Berdeja, MD, discusses the findings from the phase 2 results of ciltacabtagene autoleucel as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study.